ScripUS/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On
In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From